Maravai Lifesciences Holdings, Inc.
A maker of the raw ingredients behind mRNA vaccines and therapies, Maravai LifeSciences supplies everything from its CleanCap® capping technology to impurity-detection kits used by biopharma and diagnostics companies in roughly sixty countries through its TriLink and Cygnus brands. Formed in 2014 by Carl Hull, Eric Tardif, and the private-equity firm GTCR, it grew by buying scientifically driven companies like TriLink and Cygnus. Its CleanCap® technology was a key ingredient in the Pfizer-BioNTech COVID-19 vaccine, and its name is the northern Italian word for "miracle."
Sold 9.94M
Granted 2.00M · Bought 466.8K
Granted 2.09M
Granted 787.7K
Granted 745.4K
Granted 184.3K · Bought 100.0K
Granted 500.0K
Granted 305.1K · Bought 175.0K
Granted 526.9K
Granted 412.2K
Granted 440.4K
Granted 521.9K · Sold 75.0K
Granted 584.1K
Granted 184.3K
Granted 188.0K · Bought 17.5K
Granted 138.1K
Granted 184.3K
Granted 184.3K
Granted 184.3K
Granted 138.1K
Granted 138.1K
Granted 48.9K
Granted 4.3K
Granted 18.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| GTCR Co-Invest XI LP +7 co-filersDirector, 10% owner · 6 transactions | — | 130.83Mas of May 2024 | — | — | 9.94M |
| GTCR Co-Invest XI LP +4 co-filersDirector, 10% owner · 1 transaction | — | 119.09Mas of Jan 2023 | — | — | — |
| Brust BerndChief Executive Officer, Director · 5 transactions | — | 2.12M | 2.00M | 466.8K | — |
| Martin William E. IIIChief Executive Officer · 7 transactions | — | 1.81Mas of Mar 2025 | 2.09M | — | — |
| Leddy Peter MichaelSee Remarks · 13 transactions | — | 727.2Kas of Jul 2025 | 787.7K | — | — |
| Herde KevinChief Financial Officer · 18 transactions | +135641.6% | 674.6Kas of May 2025 | 745.4K | — | — |
| Lucier Gregory TDirector · 13 transactions | — | 622.4K | 184.3K | 100.0K | — |
| Asarpota RajeshChief Financial Officer · 1 transaction | — | 500.0Kas of Jun 2025 | 500.0K | — | — |
| Hull CarlSee Remarks, Director · 7 transactions | — | 477.1Kas of Nov 2024 | 305.1K | 175.0K | — |
| Dolan ChristineSee Remarks · 21 transactions | +46332.1% | 425.3K | 526.9K | — | — |
| Eckert R AndrewDirector · 3 transactions | — | 412.2K | 412.2K | — | — |
| Burch AndrewSee Remarks · 6 transactions | — | 369.2Kas of Jan 2025 | 440.4K | — | — |
| Oreshack KurtGeneral Counsel · 22 transactions | +4099.7% | 335.8K | 521.9K | — | 75.0K |
| Buzzeo RebeccaSee Remarks · 7 transactions | — | 310.9Kas of Mar 2025 | 584.1K | — | — |
| Gray SusannahDirector · 5 transactions | +578.8% | 216.2K | 184.3K | — | — |
| DeFord John ADirector · 5 transactions | — | 205.5K | 188.0K | 17.5K | — |
| Hopfield JessicaDirector · 4 transactions | +223.2% | 199.9Kas of Jun 2025 | 138.1K | — | — |
| Cunningham Sean LaurenceDirector · 5 transactions | — | 184.3K | 184.3K | — | — |
| Marker Luke JosephDirector · 5 transactions | — | 184.3K | 184.3K | — | — |
| Mihas Constantine SDirector · 5 transactions | — | 184.3K | 184.3K | — | — |
| Prahalad MuraliDirector · 7 transactions | +417.9% | 154.6Kas of Jun 2025 | 138.1K | — | — |
| Daverman Benjamin JamesDirector · 4 transactions | — | 138.1Kas of Jun 2025 | 138.1K | — | — |
| Ashkenazi AnatDirector · 3 transactions | +412.7% | 60.8Kas of May 2024 | 48.9K | — | — |
| Hance Robert BDirector · 1 transaction | +19.5% | 26.1Kas of Nov 2021 | 4.3K | — | — |
| Neel BrianSee Remarks · 5 transactions | +5659.8% | 16.5Kas of Feb 2023 | 18.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -9.26M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.